Core Points - STRATA Skin Sciences, Inc. has successfully closed a registered direct offering, issuing 1,097,547 shares of common stock at a price of $2.204 per share [1][2] - The gross proceeds from this offering amounted to approximately $2.42 million, which will be utilized for working capital and general corporate purposes [2] - The offering was conducted under a shelf registration statement declared effective by the SEC on December 18, 2024, with a prospectus supplement filed on September 3, 2025 [3] Company Overview - STRATA Skin Sciences is focused on developing, commercializing, and marketing innovative products for treating dermatologic conditions, including psoriasis, vitiligo, and acne [4] - The company's product lineup features the XTRAC excimer laser, VTRAC lamp systems, and the TheraClearX Acne Therapy System [4] - STRATA employs a unique Partnership Program that offers a fee per treatment cost structure, on-site training, service and maintenance, and co-op advertising support [5]

Core Viewpoint - STRATA Skin Sciences, Inc. has announced a registered direct offering of 1,097,547 shares of common stock at a price of $2.204 per share, aiming to raise approximately $2.42 million for working capital and general corporate purposes [1][3]. Group 1: Offering Details - The offering is being facilitated by Ladenburg Thalmann & Co. Inc. as the exclusive placement agent, with the closing expected around September 4, 2025, pending customary closing conditions [2]. - The gross proceeds from the offering, before deducting fees and expenses, are projected to be about $2.42 million [3]. Group 2: Company Overview - STRATA Skin Sciences is focused on developing and marketing innovative products for dermatologic conditions, including psoriasis, vitiligo, and acne, with products like the XTRAC excimer laser and TheraClearX Acne Therapy System [6]. - The company employs a unique Partnership Program that offers a fee per treatment cost structure, providing on-site training, service, maintenance, and advertising support to practices [7].

Core Points - AirNet Technology Inc. has entered into a definitive agreement for the purchase and sale of 80,826,225 ordinary shares and accompanying warrants at a combined purchase price of $2.227 per share and warrant [1] - The gross proceeds from the offering are expected to be approximately $180.0 million before deducting offering expenses [1] - The offering is expected to close on or about August 27, 2025, subject to customary closing conditions [1] Financial Details - The warrants are immediately exercisable at an exercise price of $3.3405 per ordinary share and will expire five years from the date of issuance [1] - The net proceeds from the offering will be used for general corporate and working capital purposes [2] Regulatory Information - The securities will be offered pursuant to an effective "shelf" registration statement on Form F-3 previously filed with the SEC [3] - Additional information regarding the offering will be included in a current report on Form 6-K to be furnished by the Company to the SEC [2][3]

Core Viewpoint - Ocugen, Inc. has entered into a securities purchase agreement with Janus Henderson Investors to raise capital through a registered direct offering of common stock and warrants, aiming to enhance its financial position for ongoing gene therapy developments for blindness diseases [1][3]. Group 1: Offering Details - The company will sell 20,000,000 shares of common stock at a price of $1.00 per share, with warrants to purchase an additional 20,000,000 shares at an exercise price of $1.50 per share [1][3]. - The gross proceeds from the offering are expected to be approximately $20 million, with potential additional proceeds of up to $30 million if the warrants are fully exercised [3]. - The offering is expected to close on or about August 11, 2025, subject to customary closing conditions [3]. Group 2: Company Background - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a modifier gene therapy platform to address complex diseases caused by imbalances in multiple gene networks [5]. - The company is developing programs for inherited retinal diseases and other blindness conditions affecting millions globally, including retinitis pigmentosa and Stargardt disease [5].

Core Viewpoint - ParaZero Technologies Ltd. has announced a registered direct offering to institutional investors, aiming to raise approximately $2.2 million through the sale of ordinary shares and pre-funded warrants at a price of $1.10 per share [1][3]. Group 1: Offering Details - The offering includes the sale of 2,000,001 ordinary shares or pre-funded warrants at a public offering price of $1.10 per ordinary share [2]. - Pre-funded warrants are immediately exercisable and can be exercised at any time until fully exercised, with a one-for-one decrease in the number of ordinary shares for each pre-funded warrant sold [2]. - The transaction is expected to close on or about August 5, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Company Overview - ParaZero Technologies Ltd. is an aerospace defense company specializing in smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry [7]. - The company was founded in 2014 and is recognized for its advanced drone technologies, supporting various commercial, industrial, and governmental operations worldwide [7]. - Key products include SafeAir (an autonomous parachute recovery system), DefendAir (a counter-UAS net-launching platform), and DropAir (a precision aerial delivery system) [7].

Core Viewpoint - NEXGEL, Inc. has announced a definitive agreement for the issuance and sale of 413,044 shares of common stock at $2.30 per share, along with unregistered warrants for an additional 206,522 shares at an exercise price of $4.25, aimed at strengthening its balance sheet and providing working capital for anticipated growth in the second half of the year [1][2]. Group 1: Financial Details - The total number of shares being offered is 413,044 at a price of $2.30 each [1]. - Concurrently, NEXGEL will issue unregistered warrants to purchase up to 206,522 shares at an exercise price of $4.25, which are immediately exercisable for five years [1][2]. - The financing, combined with a recent $1 million non-dilutive advance from STADA, enhances the company's cash position [2]. Group 2: Regulatory Information - The shares are being offered under the company's shelf registration statement on Form S-3, which was declared effective by the SEC on June 7, 2023 [3]. - The unregistered warrants are offered under an exemption from registration requirements of the Securities Act [4]. Group 3: Company Overview - NEXGEL is a provider of healthcare, beauty, and OTC products, specializing in ultra-gentle, high-water-content hydrogels [6]. - The company has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels [6].

Core Viewpoint - Erayak Power Solution Group Inc. has entered into a securities purchase agreement for the sale of 107,692,307 shares at a price of $0.065 per share, aiming to raise approximately $7 million in gross proceeds [1][2]. Group 1: Offering Details - The offering involves the purchase and sale of Class A ordinary shares or pre-funded warrants, with a purchase price of $0.065 per share [1]. - The transaction is expected to close on or about August 1, 2025, pending customary closing conditions [2]. - Craft Capital Management is acting as the sole placement agent for this offering [2]. Group 2: Regulatory Information - The offering is conducted under a shelf registration statement on Form F-3, which was declared effective by the SEC on May 16, 2024 [3]. - A prospectus supplement detailing the terms of the offering will be filed with the SEC prior to closing [4]. Group 3: Company Overview - Erayak specializes in manufacturing, research and development, and wholesale and retail of power solution products, including inverters, generators, and smart chargers [6]. - The company's products are primarily used in agricultural and industrial vehicles, recreational vehicles, and outdoor living products [6].

Core Viewpoint - Garden Stage Limited has entered into a definitive agreement for a registered direct offering of 38,406,345 ordinary shares at a price of $0.11 per share, expected to raise approximately $4.2 million in gross proceeds [1][2]. Group 1: Offering Details - The offering includes the option for pre-funded warrants at the same price, with an exercise price of $0.001 per share [1]. - The transaction is anticipated to close on or about July 25, 2025, pending customary closing conditions [2]. - The offering is conducted under a shelf registration statement previously filed and declared effective by the SEC [3]. Group 2: Company Overview - Garden Stage Limited is a Hong Kong-based financial services provider engaged in placing and underwriting services, securities dealing and brokerage, asset management, and investment advisory services [5]. - The company operates through wholly-owned subsidiaries, including I Win Securities Limited and I Win Asset Management Limited, both licensed for various regulated activities under Hong Kong's SFO [5].

Group 1 - Safety Shot, Inc. announced a registered direct offering of 28,648,648 shares of common stock at a price of $0.37 per share, raising approximately $10.6 million in gross proceeds [1][2]. - In a concurrent private placement, the company issued warrants to purchase up to 57,297,296 shares of common stock, with an exercise price of $0.37 per share, exercisable immediately and expiring in five years [2]. - The closing of the offering is expected to occur on or about July 22, 2025 [3]. Group 2 - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on November 1, 2024 [4]. - The CEO of Safety Shot emphasized that this financing is crucial for strengthening the balance sheet and supporting expanded operations following the recent merger approval with Yerbaé [5]. - Dominari Securities, LLC acted as the exclusive placement agent for the offering [5]. Group 3 - Safety Shot, Inc. is known for its patented wellness product, Sure Shot, which lowers blood alcohol content while enhancing clarity, energy, and mood [7].

Core Viewpoint - Draganfly Inc. has entered into a securities purchase agreement to raise approximately US$25 million through the sale of 4,672,895 units at a price of US$5.35 per unit [1][3]. Group 1: Offering Details - Each unit consists of one common share and one common share purchase warrant, with the warrants exercisable at CA$7.3579 per share for five years [2]. - The offering is expected to close around July 21, 2025, pending customary closing conditions [3][4]. - The offering is made under an effective shelf registration statement and a Canadian short form base shelf prospectus [5]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including funding new product capabilities, working capital, and potential acquisitions [3]. Group 3: Company Background - Draganfly Inc. is a pioneer in drone solutions, AI-driven software, and robotics, with over 25 years of innovation in various sectors including public safety and agriculture [8].